NewsKeep me informed
January 28, 2019 - San Diego, CA, USA – Researchers at Shiley-Marcos Alzheimer’s Disease Research Center (ADRC), part of University of California San Diego School of Medicine, report that autopsies of patients diagnosed with Alzheimer’s disease (AD) when they were alive – and confirmed by autopsy – indicate many cognitive issues symptomatic of the condition are less noticeable in living Hispanic patients. More...January 28, 2019
January 17, 2019 - Copenhagen, Denmark – A new study suggests that vital exhaustion – which can be perceived as an indicator of psychological distress – is a risk factor for future risk of dementia. Researchers from the Department of Public Health, University of Copenhagen have, in collaboration with the National Research Centre for the Working Environment, and the Danish Dementia Research Centre, shown that being distressed in late midlife is associated with a higher risk of dementia in later life. More...January 17, 2019
Air Pollution in Mexico City is Associated with the Development of Alzheimer’s Disease in Children and Young Adults
December 21, 2018 - Missoula, MT, USA – A new study by researchers at the Universities of Montana, Valle de México, Boise State, Universidad Veracruzana, Instituto Nacional de Pediatría and Paul-Flechsig-Institute for Brain Research heightens together with German company Analytik Jena concerns over the evolving and relentless Alzheimer’s pathology observed in young Metropolitan Mexico City (MMC) urbanites. These findings are published in the Journal of Alzheimer’s Disease. More...December 21, 2018
Issued in conjunction with The Michael J. Fox Foundation, important consensus guidelines for running proof of concept preclinical and clinical trials of drugs targeting alpha-synuclein to slow or arrest the progression of the disease published in the Journal of Parkinson’s Disease.
December 20, 2018 - Amsterdam, NL – A recently discovered protein, alpha-synuclein, has become one of the most attractive targets for developing new drugs with the potential to slow down or arrest the progression of Parkinson’s disease (PD). Experts in the field of Parkinson’s research have now proposed a roadmap for preclinical and clinical trials investigating compounds targeting alpha-synuclein. Their consensus white paper is published in the Journal of Parkinson’s Disease. More...December 20, 2018